Comparison of maintenance regimens in Acute Promyelocytic Leukemia patients.

Autor: Kilic Gunes E; University of Health and Sciences, Gulhane Training and Research Hospital, Department of Hematology, Ankara, Turkey. Electronic address: ebrukilic83@hotmail.com., Ozkurt ZN; Gazi University Faculty of Medicine, Department of Hematology, Ankara, Turkey. Electronic address: zubeydenurozkurt@yahoo.com., Yildiz S; Gazi University Faculty of Medicine, Department of Hematology, Ankara, Turkey. Electronic address: yildizseyma2014@hotmail.com., Ozet G; University of Health and Sciences, Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkey. Electronic address: gulsumozet@gmail.com., Ceran F; University of Health and Sciences, Ankara Bilkent City Hospital, Department of Hematology, Ankara, Turkey. Electronic address: ceranf@gmail.com., Albayrak M; University of Health and Sciences, Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey. Electronic address: muratalbayrak71@yahoo.com., Reis Aras M; University of Health and Sciences, Ankara Diskapi Yildirim Beyazit Training and Research Hospital, Ankara, Turkey. Electronic address: merihreis@gmail.com., Bulduk T; University of Health and Sciences, Gulhane Training and Research Hospital, Department of Hematology, Ankara, Turkey. Electronic address: tuba.kiraz@hotmail.com., Sayin S; University of Health and Sciences, Gulhane Training and Research Hospital, Department of Hematology, Ankara, Turkey. Electronic address: sayin.selim@hotmil.com., Ayli M; University of Health and Sciences, Gulhane Training and Research Hospital, Department of Hematology, Ankara, Turkey. Electronic address: ayli.meltem@gmail.com.
Jazyk: angličtina
Zdroj: Leukemia research [Leuk Res] 2023 May; Vol. 128, pp. 107055. Date of Electronic Publication: 2023 Mar 02.
DOI: 10.1016/j.leukres.2023.107055
Abstrakt: Maintenance therapy in APL is still a standard especially in high-risk patients treated with chemotherapy+ATRA combination whereas the role of the maintenance therapy in low-risk patients is controversial. This study aims to compare the efficacy and toxicity of ATRA monotherapy and ATRA+MTX+ 6-MP combination as the maintenance treatment for 2 years in APL patients who achieved molecular complete response after induction and consolidation with ATRA+chemotherapy. A total of 71 patients from 4 different centers were included in this study. After a median follow-up of 54 months (5-180 months), the 5-year RFS was 89 % in the ATRA monotherapy arm, the 5-year RFS was 78.5 % in the combined treatment arm (p = 0.643, HR:1.3, 95 % CI: 0.35-5.3). Hematological toxicity in all grades and Grade III/IV hematological toxicity was observed significantly more in the combined treatment arm than in the ATRA monotherapy arm (All grades: 76.9 % vs 18.9 %, p < 0.001; Grade III/IV: 20.5 % vs. 3.1 %, p = 0.035). Hepatotoxicity at all levels was significantly higher in the combined treatment arm than in the ATRA monotherapy arm (61.5 % vs 25 %, p = 0.002). Our study concluded that two years of ATRA monotherapy and combined maintenance therapy, both of which were found to be similar in terms of disease control and long term survival, ATRA Monotherapy could be a safer maintenance treatment option since both hematological and non-hematological toxicities were observed less often in the ATRA monotherapy arm.
Competing Interests: Conflict of Interest The authors declare that they have no conflict of interest. This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Ethical approval was waived by the local Ethics Committee of University of Health Sciences Gulhane Faculty of Medicine with its approval dated 27.06.2022 and numbered 46418926, in view of the retrospective nature of the study and all the procedures being performed were part of the routine care. Informed consent was obtained from all individual participants included in the study.
(Copyright © 2023 Elsevier Ltd. All rights reserved.)
Databáze: MEDLINE
Externí odkaz: